17,261 trials
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events
Multiple Sclerosis
Primary: Rate of Change in Brain Parenchymal Fraction — 0.107; -0.355 percentage of change in brain volume — p=0.346
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
Non-Small Cell Lung Cancer
Primary: Objective Response Rate — 10.7; 15.0; 25.0; 0.0 percentage of participants — p=0.94
Stage IV Non-small Cell Lung Cancer (NSCLC) · Recurrent Non-small Cell Lung Cancer (NSCLC) · Extensive-stage Small Cell Lung Cancer (SCLC)
Primary: Central Nervous System (CNS) Disease Control Rate (Cohort A and C) — 2; 2 Participants
Ventricular Tachycardia · Cardiomyopathy · Premature Ventricular Contractions
Primary: Number of Serious Adverse Events — 2; 0; 0; 1 Events
Colorectal Neoplasm · Colorectal Cancer
Primary: Number of Patients With Adverse Events — 5; 0 Participants
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving DAS28 Remission. — 6; 6 Participants — p=0.530
Plasma Cell Myeloma
Primary: Total Daratumumab Infusion Time — 1.5 hours
Alcoholic Hepatitis
Primary: The Number of Subjects With Unexpected Serious Adverse Events. — 0; 0; 0 Participants
Metastatic Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) Within the First Cycle of Dasatinib in Combination With Trastuzumab and Paclitaxel (Phase I) — 1; 2 Participants
Hypercholesterolaemia
Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8 — -41.1; -7.9; -40.6; -49.8 percent change
Inflammation · Coagulation · HIV Infection
Primary: Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 4 Months. — -0.02; 0.09 ln-pg/mL — p=0.26
Hodgkin Disease · Lymphoma, Large-Cell, Anaplastic
Primary: Overall Response Rate (ORR) — 70.0; 66.7 percentage of participants
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Progression-free Survival — 5; 8 months — p=0.384